Loading
A phase 3 trial of Nuvastatic 300 in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy. is a phase 3 interventional study registered as NCT07669454 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: Nuvastatic 300 and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares NatureCeuticals, Colorectal cancer and the tag pipeline.
Shares NatureCeuticals and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/